Mavacamten in Symptomatic Patients Resistant to Previous Advanced Therapy for Obstructive Hypertrophic Cardiomyopathy.

J Am Heart Assoc · 2025 · PMC12449955 · PMID 40673527

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

did not reach statistical significanceP =0.07so close (0.05 < p ≤ 0.1)

Although the rate of treatment interruption for LV systolic dysfunction in our study was numerically higher in those with prior advanced treatment, this did not reach statistical significance ( P =0.07).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.